Dr. Varsha S. Taskar, MD
Pulmonology (Pulmonary Disease Physician)
- Medicare participating
At a glance
- Years since graduation
- 37
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 445
Licensed in Texas since 1999, according to the Texas Medical Board. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Pulmonary Disease Physician primary
GA license 77382 · TX license K7629 (first issued 1999; cancelled by request) -
Sleep Medicine (Internal Medicine) Physician
GA license 77382
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Wellstar Mcg Health, Affiliated With Med Col Augusta, GA
- Piedmont Augusta Hospital Augusta, GA
- Aiken Regional Medical Center Aiken, SC
Medical groups
- Wellstar Medical Group LLC (3,093 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 445
- Services billed
- 1,171
- Patients’ average age
- 71
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 351 | 205 |
| Test to examine how well the lungs exchange gases | 217 | 205 |
| Test to measure expiratory airflow and volume | 158 | 136 |
| Test to determine lung volumes using sensors | 135 | 131 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 103 | 102 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 101 | 34 |
| Test for exercise-induced lung stress | 96 | 90 |
| Established patient office or other outpatient visit, 20-29 minutes | 56 | 53 |
| Critical care, first 30-74 minutes | 38 | 23 |
| Sleep study including heart rate, breathing, airflow, and effort | 28 | 28 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Albuterol Sulfate Hfa (albuterol sulfate) Other prescribers in Augusta, GA | 424 |
| Montelukast Sodium Other prescribers in Augusta, GA | 405 |
| Trelegy Ellipta (fluticasone/umeclidin/vilanter) Other prescribers in Augusta, GA | 391 |
| Azithromycin Other prescribers in Augusta, GA | 351 |
| Ofev (nintedanib esylate) | 232 |
| Prednisone Other prescribers in Augusta, GA | 227 |
| Furosemide Other prescribers in Augusta, GA | 222 |
| Breo Ellipta (fluticasone/vilanterol) Other prescribers in Augusta, GA | 154 |
| Ambrisentan | 124 |
| Famotidine Other prescribers in Augusta, GA | 94 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 13 companies reported 32 payments worth $977 in total to this clinician.
| Boehringer Ingelheim Pharmaceuticals, Inc. | $242 |
|---|---|
| United Therapeutics Corporation | $220 |
| Ani Pharmaceuticals, Inc. | $88.44 |
| GlaxoSmithKline, LLC. | $80.30 |
| Genzyme Corporation | $71.97 |
| Sanofi-aventis U.S. LLC | $57.48 |
| Baxter Healthcare | $44.38 |
| Merck Sharp & Dohme LLC | $44.00 |
| Food and Beverage | $919 |
|---|---|
| Education | $57.48 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Sanofi-aventis U.S. LLC Apr 30, 2025 | Education DUPIXENT · Immunology · in-kind | $57.48 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 2 companies. The companies reported $104,157 in research payments for these studies, mostly to the institutions running them.
- Verona
Verona Pharma, Inc. - Study to Evaluate ALIS (Amikacin Liposome Inhalation Suspension) in Participants With Nontuberculous Mycobacterial Lung Infection Caused by Mycobacterium Avium Complex
Insmed, Inc. · Completed · NCT04677569
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.